Lucentis and hypertension combos among new Japanese launches
This article was originally published in Scrip
Executive Summary
Japan has listed a number of important new therapies on its national health insurance reimbursement tariff, including Lucentis and two antihypertensive combinations for which peak annual sales are expected to top $400 million.